Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) CEO Najla Guthrie joined Steve Darling from Proactive to share details the company’s subsidiary, KGK Science Inc., has entered into a research services agreement with Nova Mentis Life Science Corp. Guthrie telling Proactive this agreement will see KGK administer a phase II clinical trials to test the efficacy of psilocybin-based therapeutics for the treatment of behavioural and cognitive symptoms associated with fragile X syndrome. This phase II trial is the first human research investigating the potential of a microdose of psilocybin to improve behavioural and cognitive symptoms associated with fragile X syndrome. Guthrie also shared with Proactive some details about an open label study, where Gefion Canada GT4 technology was used to successfully deliver CBD and THC to healthy volunteers in the form of a topical cream applied to the skin. Guthrie also talked about the Province of Alberta’s new regulations that would require that the administration of psychedelic drugs as an adjunct to psychotherapy take place in licensed facilities. The Government says those rules go into effect in January of 2023.
Wellbeing Digital Sciences subsidiary KGK Sciences lands another key Phase 2 clinical trial
